Design, synthesis, and biological evaluation of novel 3-oxo-2,3-dihydropyridazine derivatives as interleukin-2-inducible T-cell kinase (ITK) inhibitors

. 2025 Nov 27 ; 15 (55) : 47565-47586. [epub] 20251203

Status PubMed-not-MEDLINE Jazyk angličtina Země Velká Británie, Anglie Médium electronic-ecollection

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid41356712

This study reports the design, synthesis, and biological evaluation of a novel series of 3-oxo-2,3-dihydropyridazine derivatives, representing a previously unexplored scaffold for selective inhibition of interleukin-2-inducible T-cell kinase (ITK), with potential application in T-cell leukemia treatment. Cytotoxicity was assessed across a panel of ITK-expressing leukemia cell lines (Jurkat, CCRF-CEM), Bruton's tyrosine kinase (BTK)-positive lines (Ramos, K562), ITK/BTK-null cancer cells, and non-cancerous fibroblasts to determine therapeutic selectivity. Compound 9 emerged as the lead candidate, showing selective ITK inhibition in biochemical kinase assays (half-maximal inhibitory concentration, IC50 = 0.87 µM) with no measurable BTK inhibition, moderate cytotoxicity in Jurkat cells (cellular IC50 = 37.61 µM), and did not show measurable cytotoxicity in fibroblasts (IC50 > 50 µM). In contrast, 22 exhibited greater potency in both kinase [IC50 (ITK) = 0.19 µM] and cytotoxicity assay [IC50 (Jurkat) = 11.17 µM], but showed partial BTK inhibition, indicating reduced selectivity. Structure-activity relationship analysis indicated that the 3,5-difluorophenyl and furan-2-ylmethyl groups in 22 contributed to potency, while the 3-fluorophenyl group in 9 was associated with improved selectivity. Importantly, western blot analysis confirmed that 9 reduced phosphorylation of ITK (Tyr551/Tyr511) and downstream extracellular signal-regulated kinase 1/2 (ERK1/2) (Thr202/Tyr204) in phytohemagglutinin-stimulated Jurkat cells, supporting on-target inhibition of ITK signaling. These results position 9 as a selective ITK inhibitor with a favorable therapeutic index, establishing a foundation for further optimization and preclinical development.

Zobrazit více v PubMed

Schmidt U. Boucheron N. Kiefer F. Trends Immunol. 2017;38(5):342–355.

Huang W. Solt L. A. Wang Y. Front. Immunol. 2020;11:1986. doi: 10.3389/fimmu.2020.01986. PubMed DOI PMC

Müller A. J. Filipe-Santos O. Eberl G. Aebischer T. Späth G. F. Bousso P. Immunity. 2012;37(1):147–157. doi: 10.1016/j.immuni.2012.05.015. PubMed DOI

Gomez-Rodriguez J. Readinger J. A. Viorritto I. C. Schwartzberg P. L. Immunol. Rev. 2016;231(1):45–56. doi: 10.1111/j.1600-065X.2007.00534.x. PubMed DOI

Readinger J. A. Mueller K. L. Venegas A. M. Horai R. Schwartzberg P. L. Nat. Rev. Immunol. 2008;8(10):865–876.

Yayan J. Franke K. J. Berger M. Windisch W. Rasche K. Mol. Biol. Rep. 2024;51(1):165. doi: 10.1007/s11033-023-08920-5. PubMed DOI PMC

Liu Y. Wang X. Deng L. Cancer Cell Int. 2019;19:32. doi: 10.1186/s12935-019-0754-9. PubMed DOI PMC

Onidani K. Miura N. Sugiura Y. Abe Y. Watabe Y. Kakuya T. Mori T. Yoshimoto S. Adachi J. Kiyoi T. Kabe Y. Suematsu M. Tomonaga T. Shibahara T. Honda K. Cancers. 2021;13(13):3333. doi: 10.3390/cancers13133333. PubMed DOI PMC

Flefel E. M. Tantawy W. A. El-Sofany W. I. El-Shahat M. El-Sayed A. A. Abd-Elshafy D. N. Molecules. 2017;22(1):148. doi: 10.3390/molecules22010148. PubMed DOI PMC

Malik A. Mishra R. Mazumder R. Mazumder A. Mishra P. S. Res. J. Pharm. Technol. 2021;14(6):3423–3429.

Rimaz M. Mousavi H. Turk. J. Chem. 2013;37:252–261.

Liu Z.-Q. Zhang Q. Liu Y.-L. Yu X.-Q. Chui R.-H. Zhang L.-L. Zhao B. Ma L.-Y. Bioorg. Med. Chem. 2024;111:117847. doi: 10.1016/j.bmc.2024.117847. PubMed DOI

Charrier J. D. Miller A. Kay D. P. Brenchley G. Twin H. C. Collier P. N. Ramaya S. Keily S. B. Durrant S. J. Knegtel R. M. Tanner A. J. Brown K. Curnock A. P. Jimenez J. M. J. Med. Chem. 2011;54:2341–2353. doi: 10.1021/jm101499u. PubMed DOI

Muddasani G. Rampeesa N. K. Anugu S. Muddasani P. Gurská S. Džubák P. Hajdúch M. Das V. Gundla R. Bioorg. Med. Chem. 2025;20:118116. doi: 10.1016/j.bmc.2025.118116. PubMed DOI

Rampeesa N. K. et al. . Bioorg. Chem. 2025;157:108316. doi: 10.1016/j.bioorg.2025.108316. PubMed DOI

Vargas L. Hamasy A. Nore B. F. Smith E. Scand. J. Immunol. 2013;78:130–139. doi: 10.1111/sji.12069. PubMed DOI

Shome A. Jha K. T. Chawla P. A. SynOpen. 2023;7(4):566–569. doi: 10.1055/s-0042-1751499. DOI

Fyfe J. W. B. Fazakerley N. J. Watson A. J. B. Angew. Chem., Int. Ed. 2017;56(5):1249–1253. doi: 10.1002/anie.201610797. PubMed DOI

Noriko S., Jun E., Hiroshi N., Megumi U., Yusuke S., Yusuke I., Michiaki A., Yuichi H., Takeshi K. and Koichi Y., WO2013147183, 2013

Allwood D. M. Blakemore D. C. Brown A. D. Ley S. V. J. Org. Chem. 2014;79(1):328–338. doi: 10.1021/jo402526z. PubMed DOI

Duque R., Lorena J., Brill Z., Fradera G., Siliphaivanh X., Su P. and Jing J., WO2021252307, 2016

Buriánová R. and Kotulová J., Laboratory Techniques in Cellular and Molecular Medicine, Palacký University Olomouc, Olomouc, 1st edn, 2022, pp. 37–42

Stránská J., Laboratory Techniques in Cellular and Molecular Medicine, Palacký University Olomouc, Olomouc, 1st edn, 2022, pp. 29–36

Gurská S., Laboratory Techniques in Cellular and Molecular Medicine, Palacký University Olomouc, 1st edn, 2022, pp. 67–72

Koraboina C. P. Maddipati V. C. Annadurai N. Gurská S. Džubák P. Hajdúch M. Das V. Gundla R. ChemMedChem. 2024;19(1):e202300511. doi: 10.1002/cmdc.202300511. PubMed DOI

Pettersen F. Goddard T. D. Huang C. C. Couch S. Greenblatt D. M. Meng E. C. Ferrin T. E. J. Comput. Chem. 2004;25(13):1605–1612. doi: 10.1002/jcc.20084. PubMed DOI

Trott O. Olson A. J. J. Comput. Chem. 2010;31:455–461. doi: 10.1002/jcc.21334. PubMed DOI PMC

Ramchmilewitz J. Riely G. J. Huang J. H. Chen A. Tykocinski M. L. Blood. 2001;98:1656. PubMed

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...